Related Research Articles
Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It is perhaps best known for its involvement in developing the Oxford-Astrazeneca COVID-19 vaccine.
Sir Gregory Paul Winter is a Nobel Prize-winning British molecular biologist best known for his work on the therapeutic use of monoclonal antibodies. His research career has been based almost entirely at the MRC Laboratory of Molecular Biology and the MRC Centre for Protein Engineering, in Cambridge, England.
Celltech Group plc was a leading British-based biotechnology business based in Slough. It was listed on the London Stock Exchange and was a constituent of the FTSE 100 Index.
Servier Laboratories is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes).
Sheridan Gray Snyder OBE is an entrepreneur, venture capitalist, and philanthropist. in the biotechnology industry. He is the founder and CEO of Biocatalyst, but also a "serial entrepreneur", a founder of Genzyme and many other companies. Snyder, who was the University of Virginia's best tennis player when he was studying for his BA in French and Romance Languages there in the 1960s, made "major contributions to the popularisation of tennis in the USA." He co-founded the National Junior Tennis League that reaches 250,000 inner-city young people and constructed a new tennis center at the University of Virginia.
Alan G. Walton OBE was a scientist, businessman, and venture capitalist. He was born in England in 1936 and earned a Ph.D. from the University of Nottingham. He worked for twenty years as a professor at Case Western Reserve University and later served as the Chairman of Oxford Bioscience Corporation. Walton was instrumental in the development and funding of the Human Genome Project. Through his association with Oxford Bioscience, Walton managed over $850 million in a portfolio that included 80 companies. In 2012, he was awarded the Order of the British Empire by Queen Elizabeth II. He died in 2015 at his home in Westport, Connecticut.
Sir Neil CossonsFMA is a British historian and museum administrator.
Sir Christopher Thomas Evans is a Welsh biotechnology entrepreneur.
Sir David James Scott Cooksey is a British businessman, venture capitalist and policy advisor.
UF Innovate | Sid Martin Biotech is located in Alachua, Florida, in Progress Park. The program's mission is to foster the growth of bioscience startup companies that have some relationship to the University. The Incubator works with companies in all product areas relating to the life sciences, biomedical research, medicine, and chemical sciences.
Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology.
John McCafferty is a British scientist, one of the founders of Cambridge Antibody Technology alongside Sir Gregory Winter and David Chiswell. He is well known as one of the inventors of scFv antibody fragment phage display, a technology that revolutionised the monoclonal antibody drug discovery. McCafferty and his team developed this process following failures previously generating antibodies by immunizing mice. Later improvements of antibody phage display technology enables the display of millions of different antibody fragments on the surface of filamentous phage and subsequent selection of highly specific recombinant antibodies to any given target. This technology is widely exploited in pharmaceutical industry for the discovery and development of therapeutic monoclonal antibodies to treat mainly cancer, inflammatory and infectious diseases. One of the most successful was HUMIRA (adalimumab), discovered by Cambridge Antibody Technology as D2E7 and developed and marketed by Abbott Laboratories. HUMIRA, an antibody to TNF alpha, was the world's first phage display derived fully human antibody, which achieved annual sales exceeding $1bn therefore achieving blockbuster status. Humira went on to dominate the best-selling drugs lists - in 2016: The best selling drugs list researched by Genetic Engineering & Biotechnology News, published in March 2017, details that Humira occupied the number 1 position for 2015 and 2016. Whilst for 2017, Abbvie reports that Humira achieved $18.427billion of sales in 2017
Lindsay A. Rosenwald is an American doctor and finance expert in asset management, investment banking, venture capital and direct investing within the biotechnology and life-sciences industry, and one of two co-founders and partners of Opus Point Partners, an asset management company that invests in the healthcare space, primarily in biotechnology. He has been a prolific founder of development stage biotech companies.
The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.
Richard William Barker is a British life sciences and healthcare leader, board member, advisor, speaker and author. He is known as the Founder of New Medicine Partners and Founding Director of the University of Oxford — University College of London Centre for the Advancement of Sustainable Medical Innovation (CASMI).
Trevor Mervyn Jones, CBE PhD DSc (Hon) FRCP FMedSci FBPhS FRSM FRSC FLSW is a visiting professor at King's College London, and a former Head of R&D, at Wellcome. He continues to have a distinguished career in the pharmaceutical and biotech industry as well as in academia.
William H. Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company’s interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.
Jane Osbourn OBE is a scientist and chair of the UK BioIndustry Association.
GenScript Biotech Corporation is a global biotechnology group. Built upon leading gene synthesis technology, GenScript consists of four major groups:
References
- ↑ "Investment: The drugs don't work". The Independent. London. 22 August 2008. Retrieved 1 April 2010.
- ↑ [ dead link ]
- ↑ "No. 58014". The London Gazette (Supplement). 17 June 2006. p. 9.
- ↑ Dr David Chiswell, Glyn Edwards awarded honors, August 9, 2006, archived from the original on December 6, 2013, retrieved September 10, 2013
- ↑ The Top 100 Living Contributors to Biotechnology (PDF)
 | This United Kingdom business–related biographical article is a stub. You can help Wikipedia by expanding it. |